Connectomic Analysis of SNc and VTA Projections to the Striatum and Cortex
Objective: To investigate the dopaminergic neural tracts of healthy individuals using Diffusion MRI on Human Connectome Project Data. Background: Classically, the DA system has been…A cell-penetrating peptide (CPP) did not decrease 150-kDa BoNT/A toxin adsorption to surfaces or increase toxin potency or duration in a prototype formulation
Objective: To examine the effect of a cell-penetrating peptide (CPP) in a prototype formulation using toxin adsorption, in vivo potency, and duration analyses. Background: Unit…ADROIT study: current recruitment and DBS implant data
Objective: To characterize long-term, safety and effectiveness of Abbott DBS devices Background: ADROIT (Abbott DBS Post-Market Study of Outcomes for Indications over Time) is a…Sleep Quality and Nutrition effects in patients with Parkinson’s Disease
Objective: Establish the relationship between nutritional indicators and sleep quality index in patients with Parkinson disease. Background: One of the most frequent non-motor symptoms of…Identifying and Controlling Variability in Digital Health Measures in Parkinson’s disease Clinical Trials
Objective: The 3DT initiative of the Critical Path for Parkinson’s Consortium (CPP) aims to advance the regulatory maturity of digital biomarkers, for clinical studies in…Terminal Choking in Parkinson’s Disease
Objective: To establish whether choking is a frequent cause of death in Parkinson’s Disease (PD), if this is a feared consequence of PD in patients/caregivers…Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease: Efficacy, Safety, and Tolerability Data from the Second Cohort at 6 Months
Objective: Results from cohort 2 in the Phase 1/2 SUNRISE-PD study (NCT03720418) at 6 months (6M) post administration of AXO-Lenti-PD (ALPD) gene therapy are presented.…Effect of probiotics on MDS UPDRS in Parkinson disease at 12 weeks: A Randomized double-blind placebo-controlled trial
Objective: The primary objective was to find the effect of 12 weeks of probiotic supplementation on MDS UPDRS score in Parkinson’s Disease. The secondary objectives…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Dyskinesia
Objective: Assess impact of apomorphine sublingual film (APL) on time spent with and functional impact of dyskinesia among patients with Parkinson’s disease (PD) and “OFF”…Blindness analyses in STEADY-PD3: a phase III placebo-controlled double-blind randomized trial of Isradipine as a disease modifying agent in early Parkinson Disease
Objective: To describe blindness for treatment allocation in STEADY-PD3 and understand the reasons for perceived treatment allocation. Background: The use of a placebo arm aims…
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 132
- Next Page »